Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CPB1 | P15086 | 2/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17000243 | 0.83 | L3MBTL1 (0.44) | L3MBTL1NAMPTKCNH2KDM5BPRMT5 | |
| SCHEMBL19934576 | 0.82 | NAMPT (0.40) | NAMPTKCNH2CPB1CPB2KDM5B | |
| SCHEMBL18083219 | 0.81 | L3MBTL1 (0.50) | L3MBTL1NAMPTKCNH2KDM5BPRMT5 | |
| SCHEMBL25123774 | 0.81 | NAMPT (0.34) | L3MBTL1NAMPTJAK2JAK1JAK3 | |
| SCHEMBL16805456 | 0.80 | NAMPT (0.40) | L3MBTL1NAMPTKCNH2CPB1CPB2 | |
| SCHEMBL21502004 | 0.80 | ACHE (0.45) | L3MBTL1NAMPTKCNH2KDM5BPRMT5 | |
| SCHEMBL23634159 | 0.78 | NAMPT (0.33) | NAMPTCPB1CPB2 | |
| SCHEMBL13181029 | 0.76 | ADORA2A (0.47) | L3MBTL1NAMPT | |
| SCHEMBL24973473 | 0.76 | KCNH2 (0.36) | L3MBTL1KCNH2JAK3 | |
| SCHEMBL23278255 | 0.76 | LMNA (0.38) | L3MBTL1NAMPTJAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | L3MBTL1 4437/4885NAMPT 14/4885KCNH2 4273/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | L3MBTL1 4437/4885NAMPT 14/4885KCNH2 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.